Glenn  Whaley net worth and biography

Glenn Whaley Biography and Net Worth

Insider of Immunic
Glenn Whaley, CPA, joined Immunic as Principal Accounting Officer and Controller in December 2019. In April 2020, he was promoted to the position of Vice President Finance, Principal Financial and Accounting Officer. Mr. Whaley brings to Immunic more than 30 years of experience in accounting and finance.
Prior to joining Immunic, from March 2015 until May 2019, Mr. Whaley held roles of increasing responsibility at specialty pharmaceuticals company, Pernix Therapeutics, most recently serving as Vice President of Finance. Previously, Mr. Whaley was Vice President of Finance for Alvogen, Inc, a global pharmaceutical company; Corporate Controller for ImClone Systems, a biopharmaceutical company dedicated to developing biologic medicines in the area of oncology; and served in various, key financial roles in public accounting and in the pharmaceutical and telecommunications industries.
Mr. Whaley earned a Bachelor of Science degree from Rutgers University Business School and is a Member of the New Jersey Society of Certified Public Accountants and the American Institute of Certified Public Accountants.

What is Glenn Whaley's net worth?

The estimated net worth of Glenn Whaley is at least $27,295.70 as of May 15th, 2023. Mr. Whaley owns 25,510 shares of Immunic stock worth more than $27,296 as of November 21st. This net worth estimate does not reflect any other investments that Mr. Whaley may own. Additionally, Mr. Whaley receives a salary of $576,850.00 as Insider at Immunic. Learn More about Glenn Whaley's net worth.

How old is Glenn Whaley?

Mr. Whaley is currently 56 years old. There are 5 older executives and no younger executives at Immunic. The oldest executive at Immunic is Dr. Andreas Muehler M.D., Ph.D., Chief Medical Officer, who is 59 years old. Learn More on Glenn Whaley's age.

What is Glenn Whaley's salary?

As the Insider of Immunic, Inc., Mr. Whaley earns $576,850.00 per year. There are 2 executives that earn more than Mr. Whaley. The highest earning executive at Immunic is Dr. Daniel Vitt Ph.D., CEO, President & Director, who commands a salary of $869,960.00 per year. Learn More on Glenn Whaley's salary.

How do I contact Glenn Whaley?

The corporate mailing address for Mr. Whaley and other Immunic executives is 1200 AVENUE SUITE 200, NEW YORK NY, 10036. Immunic can also be reached via phone at (332) 255-9818 and via email at [email protected]. Learn More on Glenn Whaley's contact information.

Has Glenn Whaley been buying or selling shares of Immunic?

Glenn Whaley has not been actively trading shares of Immunic within the last three months. Most recently, on Monday, May 15th, Glenn Whaley bought 5,000 shares of Immunic stock. The stock was acquired at an average cost of $1.75 per share, with a total value of $8,750.00. Following the completion of the transaction, the chief financial officer now directly owns 25,510 shares of the company's stock, valued at $44,642.50. Learn More on Glenn Whaley's trading history.

Who are Immunic's active insiders?

Immunic's insider roster includes Duane Nash (Chairman), Daniel Vitt (CEO), and Glenn Whaley (Insider). Learn More on Immunic's active insiders.

Are insiders buying or selling shares of Immunic?

In the last twelve months, Immunic insiders bought shares 1 times. They purchased a total of 87,300 shares worth more than $100,395.00. The most recent insider tranaction occured on November, 12th when Director Richard Alan Rudick bought 87,300 shares worth more than $100,395.00. Insiders at Immunic own 3.0% of the company. Learn More about insider trades at Immunic.

Information on this page was last updated on 11/12/2024.

Glenn Whaley Insider Trading History at Immunic

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
5/15/2023Buy5,000$1.75$8,750.0025,510View SEC Filing Icon  
11/7/2022Buy5,000$1.50$7,500.0020,510View SEC Filing Icon  
6/3/2022Buy3,500$3.04$10,640.0012,568View SEC Filing Icon  
5/12/2022Buy3,000$5.08$15,240.009,068View SEC Filing Icon  
8/10/2021Buy1,500$9.85$14,775.003,500View SEC Filing Icon  
8/10/2020Buy1,000$18.96$18,960.001,000View SEC Filing Icon  
See Full Table

Glenn Whaley Buying and Selling Activity at Immunic

This chart shows Glenn Whaley's buying and selling at Immunic by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Immunic Company Overview

Immunic logo
Immunic, Inc., a biotechnology company, develops a pipeline of selective oral immunology therapies for the treatment of chronic inflammatory and autoimmune diseases in the United States and Germany. Its lead development program is IMU-838, which is in Phase 3 clinical trial, for treatment of multiple sclerosis, including relapsing and progressive multiple sclerosis; and moderate-to-severe ulcerative colitis. The company is also developing IMU-856, which is entering Phase 2 clinical trial, for the restoration of the intestinal barrier function in patients suffering from gastrointestinal diseases, such as celiac disease, inflammatory bowel disease, short bowel syndrome, irritable bowel syndrome with diarrhea, and other intestinal barrier function diseases; and IMU-381, which is in preclinical trial, for the treatment of gastrointestinal diseases. Immunic, Inc. was founded in 2016 and is headquartered in New York, New York.
Read More

Today's Range

Now: $1.07
Low: $1.02
High: $1.08

50 Day Range

MA: $1.42
Low: $1.05
High: $1.95

2 Week Range

Now: $1.07
Low: $0.97
High: $2.11

Volume

481,762 shs

Average Volume

962,999 shs

Market Capitalization

$96.39 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.88